Company profile: Vicebio
1.1 - Company Overview
Company description
- Provider of next-generation respiratory virus vaccines leveraging Molecular Clamp platform technology to stabilize viral glycoproteins in pre-fusion conformation, delivering broad protection and ready-to-use formulations. Pipeline includes bivalent RSV/hMPV (VXB-241), trivalent RSV-hMPV-PIV3, influenza A, SARS-CoV-2, and candidates for MERS, Ebola, and Nipah.
Products and services
- Molecular Clamp Technology: Platform-level system that stabilizes viral glycoproteins in their pre-fusion conformation, enabling highly protective, ready-to-use vaccines and underpinning a multipathogen respiratory vaccine pipeline delivering broad protection
- Trivalent RSV-hMPV-PIV3 Vaccine Candidate: Trivalent product engineered with Molecular Clamp-stabilized viral glycoproteins to target RSV, hMPV, and PIV3, delivering protective immunity against these respiratory viruses
- VXB-241 Vaccine Candidate: Bivalent vaccine constructs targeting RSV and hMPV using Molecular Clamp-stabilized pre-fusion glycoproteins, architected to induce high levels of neutralizing antibodies against both pathogens
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vicebio
Generate:Biomedicines
HQ: United States
Website
- Description: Provider of a machine learning-powered platform to create new drugs on demand across biologic modalities, accelerating therapeutic identification and validation; Chroma, an open-source AI model that programs novel proteins with targeted properties; and a clinical pipeline (GB-0895 for asthma, GB-0669 targeting SARS-CoV-2), with an expanded collaboration with Amgen to develop novel proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Generate:Biomedicines company profile →
Q-linea
HQ: Sweden
Website
- Description: Provider of applications and systems for detecting, for example, biological warfare agents; a privately held company that develops and sells these detection applications and systems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Q-linea company profile →
RQx Pharmaceuticals
HQ: United States
Website
- Description: Provider of broad spectrum antibiotic development; a biopharmaceutical company founded in 2010 and based in La Jolla, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RQx Pharmaceuticals company profile →
OLM Diagnostics
HQ: United Kingdom
Website
- Description: Provider of fungal and bacterial diagnostic solutions for healthcare providers, including: AspLFD, a lateral flow device detecting Aspergillus antigens in 15–40 minutes; AspID and PneumID real-time PCR kits for Aspergillus species (90 minutes) and Pneumocystis jirovecii (45 minutes); CandID for early Candida bloodstream detection; and AurisID for identifying Candida auris.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OLM Diagnostics company profile →
Rebiotix
HQ: United States
Website
- Description: Provider of microbiome-based therapeutics targeting GI diseases, including FDA-approved REBYOTA for prevention of recurrence of Clostridioides difficile infection in adults; RBX2660, a live biotherapeutic in development for recurrent C. difficile; RBX7455, a non-frozen capsule in feasibility studies; and a Stool Donor Program supporting development of microbiome-based therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rebiotix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vicebio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vicebio
2.2 - Growth funds investing in similar companies to Vicebio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vicebio
4.2 - Public trading comparable groups for Vicebio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →